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Abstract
Background and Aims: Although costly and uncomfortable for the patient, the current standard to 
assess mucosal healing in Crohn’s disease [CD] patients is endoscopy. The aim of this study was to 
evaluate NGAL-MMP-9 as surrogate marker for mucosal healing in CD patients.
Methods: Serum NGAL-MMP-9 levels were determined with sandwich enzyme-linked 
immunosorbent assay before and up to 5  years after first infliximab infusion in 108 active CD 
patients [median age at first infliximab 36 years, 57% female] and 43 healthy controls [HC, median 
age 27 years, 60% female]. Serum samples were matched to the time of endoscopy and complete 
endoscopic healing was defined as absence of ulcerations. Histological healing was defined as 
absence of epithelial damage [D’Haens score].
Results: At baseline, median [interquartile range] NGAL-MMP-9 levels were significantly higher in 
active CD patients vs HC (77.6 [36.9-141.0] vs 25.5 [17.8-42.8] ng/ml; p < 0.001). After treatment, NGAL-
MMP-9 levels significantly decreased in completely healed CD patients [n = 38] (84.5 [36.7-138.4] to 
23.4 [7.4-42.5] ng/ml; p < 0.001) and—to a lesser extent—in non-healed CD patients [n = 36] (100.9 
[43.4-152.6] to 43.8 [27.0-96.8] ng/ml; p = 0.001). Receiver operating characteristic analysis defined 
a NGAL-MMP-9 cut-off level of 45 ng/ml corresponding to complete endoscopic healing (area under 
the curve [AUC] = 0.79, 82% sensitivity, 65% specificity) and histological healing [AUC = 0.72, 79% 
sensitivity, 53% specificity]. At baseline, C-reactive protein [CRP] was not elevated in 33% of active 
CD patients, whereas 53% of these patients did have elevated NGAL-MMP-9 levels.
Conclusions: In the search for surrogate markers to assess mucosal healing in inflammatory bowel 
disease, NGAL-MMP-9 supplements and outperforms CRP in both ulcerative colitis and CD patients.
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1. Introduction
Crohn’s disease [CD] is a chronic, relapsing disease of the gastro-
intestinal tract with increasing prevalence and incidence in both 
industrialised and developing countries.1 In CD, a defective acute 
immune response with impaired neutrophil accumulation and inter-
leukin [IL]-8 production is observed.2,3 This may lead to delayed 
or incomplete removal of bacteria that breach the mucosal barrier. 
These bacteria will subsequently be taken up by macrophages4 that 
elicit a granulomatous reaction5 and produce a secondary chronic 
inflammation.3 However, neutrophil migration to the active site of 
inflammation is stimulated by bacterial components, eg through the 
pro-inflammatory NOD2/CARD15 pathway.
The primary function of neutrophils is to kill bacteria, with 
the use of potent digestive enzymes present in and secreted from 
the granules. Neutrophil gelatinase B-associated lipocalin [NGAL, 
lipocalin-2]6,7 is found in secondary neutrophil granules. NGAL is 
expressed in response to Toll-like receptor activation during infec-
tions8,9 and can inhibit bacterial growth by sequestering iron-laden 
siderophores.10 Moreover, NGAL has been correlated with param-
eters of active disease in IBD patients.11–16 Tertiary neutrophil gran-
ules contain matrix metalloproteinase-9 [MMP-9, gelatinase B], 
a member of the MMP family.17 MMPs are zinc-dependent endo-
peptidases involved in many developmental processes, including 
angiogenesis, wound healing, and extracellular matrix [ECM] degra-
dation. Dysregulated MMP-9 levels have been previously described 
in inflammatory bowel disease [IBD].11,18,19,20,21,22,23,24,25,26 Recently, 
the EMBARK study showed that a combination of fecal calprotec-
tin, serum MMP-9, and serum IL-22 had a strong association with 
imaging/endoscopy-defined inflammation.27 Moreover, neutralising 
antibodies with tissue inhibitor of MMPs [TIMP]-like mechanisms 
against MMP-2 and MMP-9 were shown to attenuate the develop-
ment of colitis in IBD mouse models.28 In addition to their separate 
circulating forms, MMP-9 and NGAL occur in covalent complexes, 
mainly in neutrophil degranulates.17 However, the functional role 
of this NGAL-MMP-9 complex is still debated. One hypothesis is 
that by formation of this complex, NGAL protects MMP-9 from 
autodegradation.29
In a few studies, NGAL or MMP-9 levels were investigated 
separately in blood or biopsies after anti-inflammatory treatment in 
patients with CD.30,31 Based on our original view that by measuring 
the covalent complex of NGAL with MMP-9 we would evaluate two 
markers in one assay and eventually combine the information con-
tent of two assays, we recently described that serum NGAL-MMP-9 
complex levels decrease after infliximab treatment in ulcerative coli-
tis [UC] patients achieving mucosal healing, and that levels correlate 
well with the Mayo endoscopic subscore.32 With the present study, 
we aimed to investigate whether NGAL-MMP-9 complex levels are 
elevated in CD patients in comparison with healthy controls and 
whether levels decrease after anti-inflammatory treatment in patients 
with mucosal healing. Moreover, since C-reactive protein [CRP] is 
not elevated in 20–30% of CD patients,33 we aimed to compare the 
diagnostic accuracy of NGAL-MMP-9 with CRP.
2. Materials and Methods
2.1. Patient sampling
Consecutive serum sampling and endoscopy were performed in 
108 CD patients before and after first treatment with infliximab 
[Remicade; Centocor]. Baseline characteristics of the CD patients 
are shown in Table  1. The baseline samples were obtained from 
active CD patients within 1 month before first infusion of infliximab, 
and follow-up samples were obtained up to 5  years after start of 
treatment. The median (interquartile range [IQR] time to follow-up 
endoscopy was 13 [6–54] weeks. The median [IQR] interval between 
follow-up serum sampling and last infusion with infliximab was 49 
[30–57] days. Serum samples were matched to a current endoscopy 
with a maximum interval of 30 days between serum sampling and 
time of endoscopy. CRP levels and neutrophil counts were measured 
in a centralised laboratory facility before and after infliximab, at 
time points corresponding to endoscopy. Furthermore, we collected 
serum samples from 43 healthy [non-IBD] controls [HC, median age 
27 years, 60% female]. From all individuals written informed con-
sent was obtained, and the study was approved by the University 
Hospital Ethics Committee (Vlaams erfelijkheidsonderzoek Crohn 
en colitis ulcerosa [VLECC] S-53684).
2.2. Definition of endoscopic and histological 
healing
Endoscopic mucosal healing was determined by expert gastroenter-
ologists [SV, MF, PR, and GVA] at follow-up endoscopic evaluation. 
Complete endoscopic healing was defined as absence of ulcerations, 
whereas partial healing was defined as significant endoscopic improve-
ment but with ulcerations still present. Histopathological analysis was 
performed on mucosal biopsies stained with haematoxylin and eosin 
[H&E]. The pathologist [GDH] was blinded to the patient identity [ID], 
disease status, and treatment. The slides were scored using the D’Haens 
histological scoring system34 which comprises 8 subcategories mount-
ing to a maximum total score of 16 (also presented in Supplementary 
Table 1 [available as Supplementary Data at JCC online])]. Histological 
healing was defined as an absence of epithelial damage.
2.3. Sandwich ELISA
The commercial anti-human NGAL-MMP-9 complex ELISA [enzyme-
linked immunosorbent assay] kit [R&D Systems, Abingdon, UK] was 
used to determine NGAL-MMP-9 complex levels in the serum of CD 
patients and HC according to the manufacturer's guidelines. Briefly, 
two antibodies with different antigen specificities were used: an 
antibody directed towards MMP-9 was pre-coated on the plate and 
another against NGAL was used as the detection antibody. Hence, 
only NGAL-MMP-9 complexes were measured. The absorbance was 
measured at 450 nm with a spectrophotometer [Omega, Nazareth, 
Belgium]. NGAL-MMP-9 complex levels were quantified with the 
use of a calibration curve using purified human NGAL-MMP-9 as a 
standard [Mars software, BMG Labtech, Ortenberg, Germany].
2.4. Statistical analysis
Data were analysed with SPSS Statistics 20.0 software [SPSS Inc., 
Chicago, IL] with the use of the non-parametric Mann-Whitney 
U-test for unpaired samples and Wilcoxon signed rank test for paired 
samples. Spearman correlation analysis [correlation coefficient = r], 
Kendall's tau rank correlation [correlation coefficient = τ], Fisher’s 
exact test, chi square test, receiver operating characteristic [ROC] 
analysis, and binary logistic regression analysis were also performed 
in SPSS; p-values of < 0.05 were considered significant.
3. Results
3.1. Serum NGAL-MMP-9 complex levels are 
increased in active CD patients and decrease after 
treatment with infliximab
Complete mucosal healing with absence of ulcerations at follow-
up endoscopy was seen in 38 CD patients [35%] after treatment; 
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34 patients [32%] presented clear endoscopic improvement, but 
some ulcerations could still be observed. In contrast, 36 CD patients 
[33%] did not show any signs of endoscopic improvement or pre-
sented even worsened lesions. Serum NGAL-MMP-9 complex levels 
were elevated at baseline in active CD patients as compared with 
HC [p < 0.001] [Figure 1A and Table 2]. After treatment, NGAL-
MMP-9 levels significantly decreased in completely healed CD 
patients [p < 0.001], although four patients [10%] showed increased 
NGAL-MMP-9 levels after therapy [Figure 1A and Table 2]. Patients 
with partial healing had mild decrease of NGAL-MMP-9 levels after 
treatment [p  =  0.048] [Figure  1A and Table  2], and the decrease 
of NGAL-MMP-9 levels [difference between before and after treat-
ment] was significantly lower than in patients with complete healing 
[p = 0.001]. Moreover, 10 patients with partial healing [34%] had 
increased levels after treatment. In non-healed CD patients, NGAL-
MMP-9 serum levels also decreased after treatment [p  =  0.001] 
[Figure 1A and Table 2]. However, the decrease was significantly less 
profound than in completely healed CD patients [p  =  0.020]. No 
significant difference in extent of decrease of NGAL-MMP-9 levels 
was observed in completely healed patients compared with partially 
healed patients [p = 0.294]. Moreover, NGAL-MMP-9 levels in com-
pletely healed CD patients decreased after treatment to levels equiva-
lent to HC levels (median [IQR] 23.4 [7.4-42.5] vs 25.5 [17.8-42.8]; 
p = 0.131), whereas NGAL-MMP-9 levels in partially healed or non-
healed CD patients remained elevated after treatment in comparison 
with HC levels (median [IQR] 43.5 [18.7-61.8] and 43.8 [27.0-96.8] 
vs 25.5 [17.8-42.8]; p = 0.041 and p = 0.016, respectively) [Figure 1A 
and Table 2]. No significant differences were found between NGAL-
MMP-9 levels in completely, partially, or non-healed CD patients at 
start of treatment [Figure 1A and Table 2].
Finally, we investigated whether patients at time of follow-up 
endoscopy were maintained under the same type of concomitant 
treatment as at the time of first infliximab infusion. We found that 
56%, 83%, 96%, and 73% of the patients who received 5-amino-
salicylic acid [5-ASA], azathioprine/6-mercaptopurine [AZA/6-MP], 
methotrexate [MTX], or corticosteroids, respectively, were main-
tained on the same concomitant treatment at follow-up endoscopy. 
A proportion of patients stopped 5-ASA or corticosteroid treatment. 
However, we recorded no influence of the type of concomitant treat-
ment at follow-up endoscopy on the outcome of mucosal healing 
[Supplementary Table  2, available as Supplementary Data at JCC 
online].
3.2. Serum NGAL-MMP-9 complex levels correlate 
with neutrophil counts and complement CRP as an 
inflammatory marker
To assess its role as a serum marker of inflammation and mucosal 
healing, we correlated serum NGAL-MMP-9 complex levels with 
neutrophil counts and CRP levels. NGAL-MMP-9 serum levels cor-
related well with the amount of neutrophils in the blood [Spearman’s 
rho [r]  =  0.470, p  <  0.001]. For most of the patients, neutrophil 
Table 1. Patient characteristics and laboratory markers at the start of first treatment with infliximab for CD patients with complete, partial, 
and no mucosal healing.
Baseline patient characteristics CH [n = 38] PH [n = 34] NH [n = 36] p-value*
Male/female [%] 14/24 [37/63] 16/18 [47/53] 16/20 [44/56] 0.66b
Median [IQR] age at first infliximab [years] 41.0 [30.8-50.3] 34.3 [25.8-43.6] 34.7 [23.7-45.6] 0.21a
Median [IQR] duration of disease prior to first infliximab [years] 7.5 [3.0-21.9] 7.6 [3.5-16.0] 11.6 [2.0-18.6] 0.93a
Median [IQR] CRP at first infliximab [mg/l] 6.4 [1.7-26.5] 13.5 [7.5-31.2] 16.5 [3.3-29.7] 0.09a
Normal CRP [< 5 mg/l] levels at baseline [%] 18 [47] 7 [21] 11 [31] 0.05b
Median [IQR] amount of neutrophils [109/l] 5.8 [4.5-8.0] 5.8 [4.2-7.5] 6.2 [4.3-7.9] 0.71a
Active smoking at first infliximab [%] 13 [38] 7 [21] 9 [27] 0.13b
Montreal classification
Age at diagnosis [%] 0.48b
 A1 [< 16 years] 4 [11] 5 [15] 5 [14]
 A2 [17–40 years] 27 [71] 26 [76] 29 [81]
 A3 [> 40 years] 7 [18] 3 [9] 2 [5]
Location of disease [%] 0.53b
 L1 [ileum] 6 [16] 3 [8] 2 [6]
 L2 [colon] 9 [24] 6 [18] 10 [27]
 L3 [ileocolon] 23 [60] 25 [74] 24 [67]
 L4 [upper GI] 1 [3] 0 [0] 2 [6]
Disease behaviour [%] 0.77b
 B1 [non-stricturing, non-penetrating] 12 [32] 7 [21] 11 [31]
 B1p 8 [21] 4 [11] 6 [17]
 B2 [stricturing] 8 [21] 8 [24] 5 [14]
 B2p 5 [13] 8 [24] 9 [25]
 B3 [penetrating] 3 [8] 3 [9] 1 [3]
 B3p 2 [5] 4 [11] 4 [10]
Major abdominal surgery prior to first infliximab [%] 17 [45] 18 [53] 11 [31] 0.16b
Concomitant medication at first infliximab [%]
5-aminosalicylates [5-ASA] 23 [61] 17 [50] 18 [50] 0.58b
Corticosteroids 12 [32] 9 [26] 10 [28] 0.88b
Immunomodulators [AZA or MTX] 24 [63] 20 [59] 22 [61] 0.93b
AZA, azathioprine; CD, Crohn’s disease; CH, complete healer; CRP, C-reactive protein; IQR, interquartile range; MTX, methotrexate; NH, no healer; p, peri-
anal disease modifier; PH, partial healer.
*p < 0.05 was considered significant and the statistical difference was analysed by aKruskal-Wallis test or bchi square test.  by guest on N
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counts were found to be in the clinically determined interval of 
2.5–7.8 109/l. Nevertheless, 25% of the CD patients presented with 
neutrophilia [> 7.8 109/l]. Neutrophil counts significantly decreased 
after treatment in completely healed CD patients [p < 0.001] [Table 2 
and Figure 1C], whereby 13% of the patients showed neutropenia 
with neutrophil counts lower than 2.5 109/l. CD patients with partial 
healing after treatment also showed a decrease in neutrophil counts 
[p = 0.002] [Table 2 and Figure 1C]. However, this decrease had a 
trend to be less profound than in patients with complete healing 
[p = 0.118]. In CD patients without healing, neutrophil counts also 
decreased after treatment [p = 0.005], but to a lesser extent than in 
patients with complete healing [p = 0.153] [Table 2 and Figure 1C]. 
The decrease of neutrophil counts was not significantly different 
between partially healed or non-healed CD patients [p  =  0.928]. 
Furthermore, no significant difference was observed between base-
line neutrophil counts of CD patients with complete healing com-
pared with CD patients without mucosal healing [p = 0.95] [Table 2 
and Figure 1C]. The amount of neutrophils correlated with CRP lev-
els [r = 0.357, p < 0.001]. In patients with high CRP levels, the neu-
trophil count was also elevated [> 5.4 109/l] in 56% of the patients 
whereas, in patients with low CRP levels, 70% of the patients also 
had low neutrophil levels. In cases of low or high NGAL-MMP-9 
levels, neutrophil counts were high [> 5.4 109/l] in 58% of patients 
with high NGAL-MMP-9 [> 45 ng/ml], and in 73% of the patients 
neutrophils counts were low [< 5.4 109/l] when NGAL-MMP-9 
was also low [< 45 ng/ml]. Furthermore, we calculated the ratio of 
NGAL-MMP-9 levels over the amount of neutrophils [ng/ml/109/l] 
to investigate whether the decrease of NGAL-MMP 9 levels only 
reflected the decrease in number of neutrophils. With ROC analy-
sis, an area under the curve [AUC] of 0.74 could be determined for 
the ratio to discriminate complete mucosal healing [Supplementary 
Figure 1, available as Supplementary Data at JCC online], which was 
lower than the AUC of NGAL-MMP-9 as such [AUC = 0.78].
A good correlation was detected between NGAL-MMP-9 and 
CRP levels [r = 0.448, p < 0.001]. In 67% of active CD patients, CRP 
levels were elevated [>5 mg/l] at start of treatment with infliximab. 
After treatment, CRP levels significantly decreased in CD patients 
with complete and partial mucosal healing [p < 0.001 and p < 0.001, 
respectively] [Table 2 and Figure 1B]. We observed no significant dif-
ference in the decrease of CRP levels between complete and partially 
healed patients [p = 0.420]. CRP levels also decreased in CD patients 
without mucosal healing after treatment [p = 0.037] [Table 2 and 
Figure 1B]. However, the decrease of CRP levels was more profound 
in complete or partial CD healers after treatment than in CD non-
healers [p = 0.104 and p = 0.003, respectively]. Of importance, CRP 
was not elevated [< 5mg/l] in 33% of patients with active disease at 
start of treatment, whereas 53% of these patients did have elevated 
[> 45 ng/ml] NGAL-MMP-9 levels. Moreover, 47% of the patients 
Table 2. Overview of NGAL-MMP-9, CRP and neutrophil counts in CD patients before and after treatment with infliximab.
NGAL-MMP-9 [ng/ml] CRP [mg/l] #neutrophils [109/l]
HC [n = 43] median [IQR] 25.5 [17.8-42.8] NA NA
CH [n = 38] median [IQR] Before IFX 84.5 [36.7-138.4] 6.4 [1.7-26.5] 5.8 [4.5-8.0]
After IFX 23.4 [7.4-42.5] 2.3 [1.0-4.6] 4.0 [3.2-5.0]
p-value* < 0.001 < 0.001 < 0.001
PH [n = 34] median [IQR] Before IFX 57.0 [30.0-136.5] 13.5 [7.5-31.2] 5.8 [4.2-7.5]
After IFX 43.5 [18.7-61.8] 3.0 [1.8-7.2] 4.4 [2.9-6.3]
p-value* 0.048 < 0.001 0.002
NH [n = 36] median [IQR] Before IFX 100.9 [43.4-152.6] 16.5 [3.3-29.7] 6.2 [4.3-7.9]
After IFX 43.8 [27.0-96.8] 6.3 [2.6-21.5] 5.0 [3.1-6.3]
p-value* 0.001 0.037 0.005
CH, complete healer; IFX, infliximab; IQR, interquartile range; MMP-9, matrix metalloproteinase-9; NA, not available; NGAL, neutrophil gelatinase B-associ-
ated lipocalin; NH, no healer; PH, partial healer; CRP, C-reactive protein; CD, Crohn’s disease; HC, healthy control.
*p<0.05 was considered significant and the statistical difference was analyzed by Wilcoxon signed-rank test.
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Figure 1. Serum NGAL-MMP-9 complex [A], C-reactive protein [CRP] [B], and blood neutrophil [C] levels before and after therapy with infliximab in Crohn’s 
disease [CD] patients with complete [CH], partial [PH], and no healing [NH]. Healthy control levels of NGAL-MMP-9 are also depicted. The dotted lines represent 
the clinically used cut-off value of 5 mg/l CRP and the neutrophil count interval of 2.5–7.8 109/l; p-values < 0.001, <0 .01, and < 0.05 are depicted as ***, ** and *, 
respectively; p-values > 0.05 are indicated as NS [non-significant]. Paired data were analysed using the Wilcoxon signed rank test, whereas unpaired data were 
analysed using the Mann-Whitney U-test.
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with low CRP levels did have elevated neutrophil counts [> 5.4 
109/l]. This indicates that both NGAL-MMP-9 levels and neutrophil 
counts can be used to supplement CRP measurements in patients 
who do not present with elevated CRP levels.
3.3. Serum NGAL-MMP-9 complex levels correlate 
with endoscopic healing and are lower in patients 
with ileal disease
Serum NGAL-MMP-9 complex levels correlated with endoscopic 
scores, indicating the degree of healing [Kendall’s tau [τ] = 0.296, 
p < 0.001] as was defined at the time of endoscopic evaluation. The 
highest NGAL-MMP-9 complex levels were observed in patients 
who did not reach mucosal healing. After therapy with infliximab, 
NGAL-MMP-9 levels decreased rapidly and correlated with resto-
ration of mucosal integrity. An analogue analysis was performed 
identifying the correlation of CRP levels [τ = 0.307, p < 0.001] and 
neutrophil counts [τ = 0.239, p < 0.001] with the degree of mucosal 
healing. NGAL-MMP-9 complex levels decreased according to the 
degree of mucosal healing [Figure 2A]. In contrast, CRP was mark-
edly elevated in CD patients who did not heal, whereas CRP lev-
els in patients with partial and complete healing were similar and 
therefore not discriminative [Figure 2B]. Neutrophil count reflected 
the degree of endoscopic improvement, discriminating between no, 
partial, and complete mucosal healing [Figure 2C].
Median [IQR] NGAL-MMP-9 levels were significantly lower 
(36.8 [10.4-69.1] ng/ml) in patients with active ileal disease [n = 11] 
compared with patients with active [ileo-]colonic disease (84.0 [40.3-
147.6] ng/ml]) before start of treatment [p = 0.008] [Supplementary 
Figure 2A, B, available as Supplementary Data at JCC online]. No 
significant difference was observed in NGAL-MMP-9 levels at start 
of treatment of completely [n = 6] or partially [n = 3] healed CD 
patients with ileal disease compared with non-healed [n  =  2] CD 
patients with ileal disease [p = 0.286 and p = 0.200, respectively] 
[Supplementary Figure  2B]. Since neutrophils are the source of 
NGAL-MMP-9, we further compared the amount of neutrophils 
in patients with ileal disease with the amount in [ileo-]colonic dis-
ease. However, the difference was not significant [p = 0.069] with a 
median [IQR] neutrophil count of 5.0 [2.9-6.9] 109/l in patients with 
ileal disease and 6.0 [4.3-7.9] 109/l in patients with [ileo-]colonic 
disease.
3.4. Serum NGAL-MMP-9 complex can discriminate 
complete mucosal healing as defined by 
endoscopic evaluation
ROC analysis was performed to evaluate the performance of 
NGAL-MMP-9, CRP, and neutrophil levels to discriminate 
mucosal healing. When including patients with partial mucosal 
healing in the non-healing group of patients, the AUC for NGAL-
MMP-9 levels was 0.77, and levels lower than 45 ng/ml were 
determined to discriminate complete mucosal healing with 82% 
sensitivity, 60% specificity, 29% positive predictive value [PPV] 
and 95% negative predictive value [NPV]. The AUC for CRP 
levels was 0.74, and levels lower than 5 mg/l were able to dis-
criminate complete mucosal healing with 79% sensitivity, 57% 
specificity, 28% PPV and 93% NPV. Neutrophil levels lower than 
5.4 109/l were able to discriminate complete mucosal healing with 
an AUC of 0.68, sensitivity of 79%, specificity of 48%, 25% PPV, 
and 91% NPV.
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Figure 2. Distributions of NGAL-MMP-9 complex levels, C-reactive protein [CRP] levels and neutrophil counts with endoscopic and histological healing scores. 
The top panels illustrate the levels of NGAL-MMP-9 [A], CRP [B] and neutrophils [C] with the corresponding endoscopic healing scores, regardless of their 
response to therapy or time point before or after treatment (CH, complete healer; PH, partial healer and NH, no healer). In the lower panels, the levels of NGAL-
MMP-9 [D], CRP [E] and neutrophils [F] were grouped according to the corresponding histological healing scores (HH, histological healing and NH, no healing). 
Kendall’s tau correlation factors (T) are indicated in the top left part of each graph.
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ROC analysis, whereby patients with partial mucosal healing were 
excluded, indicated that NGAL-MMP-9 complex levels lower than 
45 ng/ml could discriminate complete mucosal healing from no heal-
ing with a sensitivity of 82% and specificity of 64% [Figure 3A and 
Table 3]. The AUC was 0.79, and a PPV of 44% and NPV of 91% 
were determined. The diagnostic accuracy of NGAL-MMP-9 was 
68%. ROC analysis with CRP levels showed a comparable AUC of 
0.75. CRP levels lower than 5 mg/l were able to discriminate complete 
mucosal healing with 79% sensitivity, 58% specificity, 39% PPV, and 
89% NPV [Figure 3A and Table 3]. To investigate the superiority of 
NGAL-MMP-9 over CRP, we analysed the performance of NGAL-
MMP-9 to discriminate complete mucosal healing in patients with low 
CRP levels at baseline. Of the 36 patients with low CRP, 18 patients 
had complete healing and 11 patients had no healing after treat-
ment. An AUC of 0.78 was determined, and a cut-off value of 38 ng/
ml NGAL-MMP-9 was able to discriminate complete mucosal heal-
ing with 83% sensitivity, 58% specificity, 47% PPV, and 88% NPV. 
Finally, a neutrophil count lower than 5.4 109/l was able to discrimi-
nate complete mucosal healing with an AUC of 0.70, 79% sensitivity, 
52% specificity, 36% PPV, and 88% NPV [Figure 3A and Table 3].
In order to investigate whether the combination of NGAL-
MMP-9 and CRP in clinical practice would improve the predic-
tion of complete mucosal healing, we performed binary logistic 
regression analysis including both parameters. With the use of the 
predicted probabilities, ROC analysis was performed and indicated 
that the combination of the two markers was able to discriminate 
complete mucosal healing with an AUC of 0.81, 82% sensitivity, 
73% specificity, 51% PPV, and 92% NPV [Figure 3A and Table 3]. 
The combination of three markers [NGAL-MMP-9, CRP, and neu-
trophils] did not improve the discriminative power [AUC of 0.81] 
as compared with the combination of two markers [NGAL-MMP-9 
and CRP].
Finally, we evaluated the diagnostic value of NGAL-MMP-9 to 
discriminate between UC and CD patients. In our previous study,32 
we identified a median [IQR] NGAL-MMP-9 level of 87.3 [43.2-
161.9] ng/ml in active UC patients before start of treatment. In the 
present CD cohort, the median [IQR] NGAL-MMP-9 level was 
77.6 [36.9-141.0] ng/ml in active patients at start of treatment 
with infliximab. Based on these data, we could not document a sig-
nificant difference between active UC and CD patients [p=0.268] 
Table 3. ROC analysis specifications of serum NGAL-MMP-9 complex values, CRP levels, neutrophil counts, and the combination of NGAL-
MMP-9 and CRP to discriminate complete endoscopic and histological healing.
Serum marker Cut-off Complete endoscopic healing Histological healing
AUC [95% CI] %sens %spec PPV NPV AUC [95% CI] %sens %spec PPV NPV
NGAL-MMP-9 45 ng/ml 0.79 [0.71-0.88] 82 64 44 91 0.72 [0.60-0.84] 79 53 29 91
CRP 5 mg/l 0.75 [0.66-0.84] 79 58 39 89 0.68 [0.58-0.79] 75 54 29 90
Neutrophils 5.4 109/L 0.70 [0.61-0.80] 79 52 36 88 0.60 [0.48-0.72] 68 46 24 85
NGAL-MMP-9 + CRP 0.34 [pred_prob] 0.81 [0.73-0.89] 82 73 51 92 0.72 [0.61-0.83] 54 79 39 87
AUC, area under the curve; sens, sensitivity; spec, specificity; PPV, positive predictive value; NPV, negative predictive value; pred_prob, predicted probability as 
defined by binary logistic regression analysis; ROC, receiver operating characteristic; CRP, C-reactive protein.
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Figure  3. Receiver operating characteristic [ROC] analysis of serum NGAL-MMP-9 complex values, C-reacive protein [CRP levels] and neutrophil counts 
corresponding to complete endoscopic [A] and histological [B] healing. The cut-off values, area under the curve [AUC], specificity, sensitivity, positive predictive 
value [PPV], and negative predictive value [NPV] of NGAL-MMP-9, CRP, neutrophil count, and the combination of NGAL-MMP-9 with CRP to discriminate complete 
mucosal healing and histological healing are shown in Table 3. The ROC curve for NGAL-MMP-9 levels is illustrated as green stripes (- - -), for CRP levels as a 
purple dotted line (…), for neutrophil count as blue alternating stripes and dots (- . -) and for the combination of NGAL-MMP-9 with CRP as a full red line (-).
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[Supplementary Figure 3, available as Supplementary Data at JCC 
online with means ± standard error of the mean].
3.5. Serum NGAL-MMP-9 complex levels correlate 
well with histological activity and can discriminate 
histological healing
Histological activity was determined in a subset of CD patients 
[n = 70] with the use of the D’Haens score. A good correlation was 
determined between endoscopic and histological activity scores 
[r  =  0.656, p  <  0.001]; 28 CD patients showed histological heal-
ing with absence of epithelial damage after treatment, of whom 21 
patients [75%] also had complete mucosal healing based on endo-
scopic evaluation and 7 [25%] had partial mucosal healing. A high 
concordance was found especially in patients with active disease, 
since all 19 patients with no endoscopic healing also had no histo-
logical healing. Of the patients with partial endoscopic healing, how-
ever, only 32% [7 out of 22] had histological healing. Importantly, 
21 out of 29 patients [72%] with complete endoscopic healing also 
had histological healing with an absence of epithelial damage.
NGAL-MMP-9 levels correlated well with histological healing 
[τ  = 0.238, p  = 0.001] [Figure 2D], whereas CRP levels and neu-
trophil count had lower correlation factors [τ  = 0.197, p  = 0.006 
and τ = 0.118, p = 0.099; respectively] [Figure 2E-F]. Intriguingly, 
NGAL-MMP-9 levels and neutrophil counts were lower in patients 
with ileal disease [see above]. Histopathological investigation 
showed that all patients with ileal disease [n = 8] had moderate infil-
tration of polymorphonuclear [PMN] cells in the lamina propria and 
no crypt abscesses were seen in the epithelium. In contrast, 15% of 
patients with [ileo-]colonic disease did have severe increase of PMN 
cells in the lamina propria, 40% of the patients had cryptitis, and 
22% presented with crypt abscesses in the epithelium.
With ROC analysis, we identified that NGAL-MMP-9 levels 
lower than 45 ng/ml could discriminate histological healing with an 
AUC of 0.72, 79% sensitivity, 53% specificity, 29% PPV, and 91% 
NPV [Figure 3B and Table 3]. In contrast, CRP levels lower than 
5 mg/l were not as potent as NGAL-MMP-9 to discriminate histo-
logical healing [AUC = 0.68, 75% sensitivity, 54% specificity, 29% 
PPV, and 90% NPV] [Figure 3B and Table 3]. A neutrophil count 
lower than 5.4 109/l was the least potent marker [AUC = 0.60, 68% 
sensitivity, 46% specificity, 24% PPV, and 85% NPV] [Figure 3B and 
Table 3]. Finally, the combination of NGAL-MMP-9 and CRP was 
not better than NGAL-MMP-9 alone to discriminate histological 
healing [AUC  =  0.72, 54% sensitivity, 79% specificity, 39% PPV, 
and 87% NPV] [Figure 3B and Table 3].
4. Discussion
Identification of non-invasive biomarkers has become an important 
research topic, since frequent endoscopic examinations are costly 
and uncomfortable for the patient. Several serological and fecal 
markers have been investigated for their use in diagnosis and assess-
ment of disease activity, but none have been shown to be superior 
to the commonly used CRP.35 In this study, we investigated the diag-
nostic accuracy of NGAL-MMP-9, CRP and neutrophil levels in a 
considerable CD cohort and found that NGAL-MMP-9 performed 
better than CRP and neutrophil count in discriminating com-
plete endoscopic and histological healing. With ROC analysis, we 
showed that NGAL-MMP-9 was the best discriminator of complete 
endoscopic healing and that the combination with CRP discretely 
enhanced the discriminative power. Importantly, we found that CRP 
was not elevated in one-third of CD patients with active disease at 
start of treatment, whereas more than half of these patients did have 
elevated NGAL-MMP-9 levels. This was further investigated by 
ROC analysis, identifying that NGAL-MMP-9 was a good surrogate 
marker to discriminate complete mucosal healing in patients with-
out elevated CRP levels at baseline. These data suggest that NGAL-
MMP-9, which is a combination of two marker molecules in one 
assay, can be considered as a new surrogate marker for IBD patients 
to assess mucosal healing and can complement or even replace CRP 
measurements. In a previous study, we already showed the value of 
the NGAL-MMP-9 complex as surrogate marker for mucosal heal-
ing in UC patients.32
Besides CRP, other markers currently used include fecal calpro-
tectin. Fecal calprotectin is a sensitive marker of intestinal inflam-
mation and correlates well with the degree of endoscopic activity.36 
Patients with ileal CD are reported to have significantly lower fecal 
calprotectin levels than those with [ileo-]colonic disease, even in 
the presence of large and/or very large ulcers.37 Moreover, the time 
of sampling during the day may affect calprotectin levels.38 In our 
cohort, we found that NGAL-MMP-9 levels were lower in patients 
with active ileal disease compared with patients with [ileo-]colonic 
disease before start of treatment [Supplementary Figure 2A, B]. Since 
neutrophils are the source of both calprotectin and NGAL-MMP-9, 
we further looked whether the amount of neutrophils was lower 
in patients with ileal disease compared with [ileo-]colonic disease; 
however, we could not document a significant difference.
A limitation of our study is the lack of fecal calprotectin meas-
urements for a direct comparison with NGAL-MMP-9. Interestingly, 
the EMBARK study showed that a combination of fecal calprotectin, 
serum MMP-9, and serum IL-22 had a strong association with imag-
ing/endoscopy-defined inflammation.27 Moreover, recent reports 
indicate the emergence of fecal MMP-9 levels in the IBD biomarker 
field. Annahazi et al. described that fecal MMP-9 is a good marker 
for the non-invasive evaluation of disease activity and mucosal heal-
ing in UC.39 Moreover, Kolho et al. showed that fecal MMP-9 per-
formed equally well as fecal calprotectin in UC, suggesting its use as 
a surrogate marker of inflammation.19 Recently, fecal MMP-9 was 
also tested in a cohort of CD patients, but was not correlated with 
any of the activity indices of CD.40 Therefore, it might be interest-
ing in the future to evaluate NGAL-MMP-9 complex levels in fecal 
samples.
As was shown by previous studies, endoscopic mucosal healing 
does not necessarily reflect quiescent histological disease.41,42 Most 
of the studies investigating histological healing were performed in 
UC patients, and there is scarce information in CD.43 In the present 
study, we used the D’Haens score34 which is also known in litera-
ture as the Colonic or Ileal Global Histologic Disease Activity Score 
[GHAS]. Despite the evidential importance of microscopic activity, 
histological remission has yet to be recommended as a therapeu-
tic endpoint for clinical trials or practice in IBD.44 In our cohort 
of CD patients, we found a good correlation between histological 
and endoscopic mucosal healing. A  high concordance was found, 
especially in patients with active disease. Importantly, 72% of the 
patients with complete endoscopic healing also had histological 
healing with an absence of epithelial damage. These data are in line 
with current literature, since it was reported that persistent histo-
logical inflammation occurs in 25–37% of patients with clinical and 
endoscopic quiescent CD.45,46
Since CD is characterised by transmural disease, endoscopic and 
histological mucosal evaluations are not able to actually determine 
‘deep’ remission in CD patients. Recent studies indicate that mag-
netic resonance enterography [MRE] can evaluate ulcer healing 
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with a high level of accuracy compared with ileocolonoscopy.47 This 
method is, however, not routinely performed in all patients, is costly, 
and requires technical and analytical skills. Moreover, it has been 
recommended that the combination of mucosal and histological 
healing should be achieved as a minimum therapeutic target in IBD 
patients.48
In order to investigate the diagnostic value of NGAL-MMP-9, 
we compared the levels between active UC and CD patients; how-
ever, we could not document a significant difference [Supplementary 
Figure 3]. Moreover, with ROC analysis we defined a higher cut-off 
value [97.7 ng/ml] in our UC cohort than in the present CD cohort 
[45 ng/ml]. This may be in part due to the fact that, in general, higher 
NGAL-MMP-9 levels were found in UC patients compared with 
CD patients. In addition, the cut-off values were chosen in order to 
identify as accurately as possible patients with mucosal healing. In 
the UC cohort, a high specificity of the test was chosen since levels 
higher than 97.7 were positively associated with no healing. In the 
present CD cohort, a high sensitivity was chosen since levels lower 
than 45 ng/ml were positively associated with complete mucosal 
healing.
Although NGAL and MMP-9 have been discussed separately 
as good markers of disease,13,14,15,16,27 our previous study in UC 
patients was the first to investigate the NGAL-MMP-9 complex 
as a surrogate serum marker of mucosal healing.32 Urinary NGAL-
MMP-9 has been reported to predict paediatric IBD,11 and in cancer 
research NGAL-MMP-9 complex is a well-known biomarker.49,50,51
In conclusion, we propose that serum NGAL-MMP-9 complex is 
useful and recommended as a surrogate marker of endoscopic and histo-
logical mucosal healing after treatment with infliximab in both UC and 
CD patients. NGAL-MMP-9 complex hereby outperforms CRP and can 
be used as a single marker in patients without elevated CRP levels or 
in combination with CRP to discriminate mucosal healing. Prospective 
studies to evaluate this new marker are needed, and the efficacy of the 
marker to discriminate mucosal healing under other emerging gut-selec-
tive biological treatments [eg vedolizumab] should be investigated.
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